Glenmark Pharmaceuticals Friday said it has received final approval from the US health regulator for its generic version of BenzaClin gel used in treatment of acne.
The approval granted to Glenmark Pharmaceuticals Inc, USA (Glenmark) by the United States Food & Drug Administration (USFDA) is for for Clindamycin and Benzoyl Peroxide Gel, 1 per cent|5 per cent, a generic version of BenzaClin1 Gel, 1 per cent|5 per cent, of Valeant Bermuda, the company said in a statement.
Citing IQVIATM sales data, Glenmark said BenzaClin Gel, 1 per cent |5 per cent had sales of USD 99.4 million in the 12-month period ended January 2019.
Glenmark's current portfolio consists of 151 products authorised for distribution in the US with 53 ANDA's (abbreviated new drug applications) pending approval with the USFDA.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app